Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports

Tumor necrosis factor (TNF)-α plays a key role in the pathogenesis of chronic inflammatory disorders; the discovery of TNF-blockers, neutralizing its biological activities, opened the way to a new efficacious therapeutic strategy. Unfortunately, the immunogenicity of anti-TNF drugs may trigger an adverse immune response with the occurrence of anti-drug antibodies (ADAs) impairing drug efficacy and safety. The increase of drug doses to overcome the effect of ADAs gives rise to many adverse effects inducing to the treatment discontinuation